Core Viewpoint - Post Holdings (POST) has been upgraded to a Zacks Rank 2 (Buy), indicating a positive outlook on its earnings estimates, which significantly influence stock prices [1][2]. Earnings Estimates and Stock Price Movement - The Zacks rating system emphasizes the correlation between changes in earnings estimates and stock price movements, making it a valuable tool for investors [2][3]. - Institutional investors play a role in this relationship, as they adjust their valuations based on earnings estimates, leading to stock price fluctuations [3]. Business Improvement Indicators - The upgrade in ratings and rising earnings estimates suggest an improvement in Post Holdings' underlying business, which could lead to an increase in stock price as investors respond positively [4]. Earnings Estimate Revisions - For the fiscal year ending September 2025, Post Holdings is projected to earn $6.63 per share, consistent with the previous year's figure, while the Zacks Consensus Estimate has increased by 3.4% over the past three months [7]. Zacks Rank System Overview - The Zacks Rank system categorizes stocks into five groups based on earnings estimates, with a strong historical performance, particularly for Zacks Rank 1 stocks, which have averaged a +25% annual return since 1988 [6]. - The upgrade of Post Holdings to a Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, indicating strong potential for market-beating returns in the near term [9].

Core Viewpoint - Qifu Technology, Inc. (QFIN) has received an upgrade to a Zacks Rank 1 (Strong Buy) due to an upward trend in earnings estimates, which is a significant factor influencing stock prices [1][4]. Earnings Estimates and Ratings - The Zacks rating system is primarily driven by changes in a company's earnings picture, specifically the Zacks Consensus Estimate for EPS from sell-side analysts [2]. - The Zacks rating upgrade for Qifu Technology indicates a positive outlook on its earnings, which could positively affect its stock price [4][6]. Impact of Earnings Estimates on Stock Prices - There is a strong correlation between changes in earnings estimates and near-term stock price movements, with institutional investors playing a role in this relationship [5]. - Rising earnings estimates and the subsequent rating upgrade suggest an improvement in Qifu Technology's underlying business, which should lead to higher stock prices [6]. Importance of Earnings Estimate Revisions - Empirical research supports the idea that tracking earnings estimate revisions can be beneficial for investment decisions, highlighting the effectiveness of the Zacks Rank stock-rating system [7]. - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with Zacks Rank 1 stocks historically generating an average annual return of +25% since 1988 [8]. Specifics on Qifu Technology's Earnings Estimates - Qifu Technology is projected to earn $7.11 per share for the fiscal year ending December 2025, with no year-over-year change expected [9]. - Over the past three months, the Zacks Consensus Estimate for Qifu Technology has increased by 2.6% [9]. Conclusion on Zacks Rating System - The Zacks rating system maintains a balanced distribution of "buy" and "sell" ratings across its universe of over 4,000 stocks, with only the top 5% receiving a "Strong Buy" rating [10]. - The upgrade of Qifu Technology to a Zacks Rank 1 places it in the top 5% of Zacks-covered stocks, indicating a strong potential for market-beating returns in the near term [11].

Core Viewpoint - AvePoint, Inc. (AVPT) has been upgraded to a Zacks Rank 2 (Buy), indicating a positive trend in earnings estimates which significantly influences stock prices [1][2]. Earnings Estimates and Stock Price Movement - The Zacks rating system highlights the strong correlation between changes in earnings estimates and near-term stock price movements, making it a valuable tool for investors [3][5]. - Institutional investors utilize earnings estimates to determine the fair value of stocks, leading to price movements based on their buying or selling activities [3]. Business Improvement Indicators - The upgrade in earnings estimates for AvePoint suggests an improvement in the company's underlying business, which could lead to higher stock prices as investors respond positively [4][9]. - AvePoint is projected to earn $0.26 per share for the fiscal year ending December 2025, with a notable increase of 400% in the Zacks Consensus Estimate over the past three months [7]. Zacks Rank System Overview - The Zacks Rank system categorizes stocks into five groups based on earnings estimates, with a proven track record of Zacks Rank 1 stocks generating an average annual return of +25% since 1988 [6][8]. - The upgrade to Zacks Rank 2 places AvePoint in the top 20% of Zacks-covered stocks, indicating strong potential for market-beating returns in the near term [9].

Core Viewpoint - Enhabit (EHAB) has received an upgrade to a Zacks Rank 2 (Buy), indicating a positive outlook on its earnings estimates, which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Price Impact - The Zacks rating system is based on changes in earnings estimates, which are strongly correlated with near-term stock price movements [4][6]. - Institutional investors often rely on earnings estimates to determine the fair value of stocks, leading to buying or selling actions that affect stock prices [4]. Company Performance and Outlook - The upgrade for Enhabit suggests an improvement in its underlying business, which could lead to increased stock prices as investors respond positively [5][10]. - For the fiscal year ending December 2025, Enhabit is expected to earn $0.44 per share, with the Zacks Consensus Estimate having increased by 18% over the past three months [8]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with a strong historical performance, particularly for Zacks Rank 1 stocks, which have generated an average annual return of +25% since 1988 [7]. - Enhabit’s upgrade to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, indicating a strong potential for market-beating returns in the near term [9][10].

Core Viewpoint - OPENLANE (KAR) has received an upgrade to a Zacks Rank 2 (Buy), indicating a positive outlook on its earnings estimates, which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Price Movement - The Zacks rating system is based on changes in earnings estimates, which have a strong correlation with near-term stock price movements [4][6]. - An increase in earnings estimates typically leads to higher fair value calculations by institutional investors, resulting in buying or selling actions that affect stock prices [4]. OPENLANE's Earnings Outlook - For the fiscal year ending December 2025, OPENLANE is expected to earn $0.98 per share, which remains unchanged from the previous year [8]. - Over the past three months, the Zacks Consensus Estimate for OPENLANE has increased by 0.3%, reflecting a positive trend in earnings estimates [8]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with Zacks Rank 1 (Strong Buy) stocks historically generating an average annual return of +25% since 1988 [7]. - OPENLANE's upgrade to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, indicating a strong potential for market-beating returns in the near term [10].

Investors might want to bet on Alight, Inc. (ALIT) , as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.Individual ...

Siemens AG (SIEGY) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.Since a changing earning ...

NexPoint Residential Trust Inc. (NXRT) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following ...

Company Overview - MiMedx (MDXG) shares increased by 8% in the last trading session, closing at $7, with higher trading volume compared to normal sessions [1] - The stock has shown a 0.5% gain over the past four weeks [1] - The rise in stock price is linked to investor optimism regarding the company's product portfolio in wound care, burn, and surgical sectors [1] Financial Performance - MiMedx is expected to report quarterly earnings of $0.06 per share, reflecting a year-over-year decline of 25% [2] - Revenue projections for the upcoming quarter are $89.28 million, which is a 2.4% increase from the same quarter last year [2] Earnings Estimates and Stock Movement - The consensus EPS estimate for MiMedx has remained unchanged over the last 30 days, indicating stability in earnings expectations [4] - Historical data suggests that stock prices typically do not continue to rise without trends in earnings estimate revisions [3][4] Industry Context - MiMedx operates within the Zacks Medical - Biomedical and Genetics industry, which includes other companies like PTC Therapeutics (PTCT) [5] - PTC Therapeutics has experienced a 0.7% decline in its stock price, with a return of -7.2% over the past month [5] - The consensus EPS estimate for PTC Therapeutics has decreased by 0.4% to -$1.07, representing a 7.8% increase from the previous year [6]

Group 1 - Hess Corporation shares increased by 4.8% to $150.23, with a higher-than-average trading volume, reflecting a 4.9% gain over the past four weeks [1] - The company has significant stakes in oil discoveries offshore Guyana and is a key partner in the ExxonMobil-led consortium in the Stabroek Block, enhancing its long-term production visibility and cash flow potential [2] - The upcoming quarterly earnings are expected to be $1.28 per share, a decrease of 51.2% year-over-year, with revenues projected at $2.67 billion, down 18.1% from the previous year [3] Group 2 - The consensus EPS estimate for Hess has been revised marginally higher in the last 30 days, indicating a potential for price appreciation [4] - Hess currently holds a Zacks Rank of 3 (Hold) within the Oil and Gas - Integrated - United States industry [5] - Calumet, Inc., another company in the same industry, has a consensus EPS estimate of -$0.42, reflecting a 12.5% year-over-year change, and also holds a Zacks Rank of 3 (Hold) [6]